CPhI Frankfurt 2025: NTC showcases its ophthalmology pipeline

  • 28 Oct, 2025

The company will highlight NT014, a fixed-dose combination eye drop developed to prevent and treat post-cataract infections, along with the Imperial line, which integrates leading technologies to enhance treatment for dry eye disease. These innovations reflect NTC’s commitment to advancing eye health through innovation, science, and strategic partnerships, setting new standards in ophthalmic care.

World Sight Day: NTC renews its partnership with Sightsavers

  • 30 Sep, 2025

A partnership to support cataract surgery for children, a condition that is currently one of the leading causes of blindness in childhood in low-income countries. This is a concrete step in our commitment to the United Nations SDG 10, which promotes the reduction of inequalities. Sight is not a privilege, but a right.

New ally against antibiotic-resistant skin infections: TiAB shows promising results

  • 12 Sep, 2025

A new in vitro study shows that a 2% concentration of TiAB—a compound based on silver-bound titanium dioxide—is sufficient to exert strong bactericidal activity within 24 hours against Gram-negative bacteria and support wound healing.

A pharmacovigilance study published confirms the safety of fixed-dose eye drops for post-cataract surgery

  • 17 Jul, 2025

This is the first international pharmacovigilance study specifically focused on a fixed-dose eye drop that combines an antibiotic and an anti-inflammatory steroid, indicated for the prevention and treatment of inflammation and the prevention of infection following cataract surgery in adults.